A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma

被引：22

作者：

Spencer, Andrew ^{[1
]}

Rosenberg, Aaron Seth ^{[2
]}

Jakubowiak, Andrzej ^{[3
]}

Raje, Noopur ^{[4
]}

Chatterjee, Manik ^{[5
]}

Trudel, Suzanne ^{[6
]}

Bahlis, Nizar J. ^{[7
]}

Siegel, David S. ^{[8
]}

Wilop, Stefan ^{[9
]}

Harrison, Simon J. ^{[10
]}

NagaKrishna, Murthy ^{[11
]}

Dhuria, Shyeilla ^{[12
]}

Hindoyan, Antreas ^{[13
]}

McIver, Zach ^{[13
]}

Henary, Haby ^{[13
]}

Morrow, Phuong Khanh ^{[13
]}

Roberts, Andrew ^{[14
,15
]}

机构：

[1] Monash Univ, Australian Ctr Blood Dis, Alfred Hosp, Melbourne, Vic, Australia

[2] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA

[3] Univ Chicago, Chicago, IL 60637 USA

[4] Massachusetts Gen Hosp, Boston, MA 02114 USA

[5] Univ Hosp Wuerzburg, Wurzburg, Bavaria, Germany

[6] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[7] Univ Calgary, Calgary, AB, Canada

[8] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[9] Rhein Westfal TH Aachen, Aachen, Germany

[10] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[11] IQVIA, Bangalore, Karnataka, India

[12] Amgen Inc, San Francisco, CA USA

[13] Amgen Inc, Thousand Oaks, CA 91320 USA

[14] Royal Melbourne Hosp, Parkville, Vic, Australia

[15] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期

关键词：

Mcl-1; inhibitor; Pharmacokinetics; Tolerability;

D O I：

10.1016/j.clml.2019.09.081

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OAB-080

引用

页码：E53 / E54

页数：2